Trial Search Results

Pilot Study of 89-Zr Panitumumab in Pancreas Cancer

The main purpose of the study is to assess the safety of 89Zr-panitumumab as a molecular imaging agent in patients with (metastatic) pancreas cancer.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University


  • Drug: 89Zr-panitumumab


Phase 1


Inclusion Criteria:

   - Confirmed diagnosis of pancreatic cancer.

Exclusion Criteria:

   - Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive
   heart failure (CHF); significant liver disease; or unstable angina within 6 months
   prior to enrollment.

   - History of infusion reactions to monoclonal antibody therapies.

   - Pregnant or breastfeeding.

   - Subjects receiving Class IA (quinidine, procainamide) or Class III (dofetilide,
   amiodarone, sotalol) antiarrhythmic agents.

   - Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis.

   - Severe renal disease or anuria.

   - Known hypersensitivity to deferoxamine or any of its components.

Ages Eligible for Study

19 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Alexander A Valencia